Managing the progression of Chronic Kidney Disease in Type 2 Diabetes

Uncontrolled diabetes and hypertension are major causes of Chronic Kidney Disease in the UK

¹

Kerendia®▼ (finerenone) targets the mineralocorticoid receptor (MR)

⁸

There is a growing body of evidence that MR overactivation leads to inflammation and fibrosis and is a key driver of CKD progression⁹

Kerendia is a selective, non-steroidal MR antagonist

⁹

Drug classes used in the management of CKD associated with T2D

Please see Safety profile section for information on hypotension and blood pressure reduction observed with Kerendia.

*SBP baseline to month 1 and month 12, -3.0 and -2.1 mm Hg respectively with finerenone and -0.1 and 0.9 mm Hg, respectively with placebo.

**Adverse reactions occurring in >1% of patients includes hypotension; the risk increases with concomitant use of multiple other antihypertensive medicines. For additional information relating to effects of Kerendia on blood pressure see safety section.

Not all treatments used to control blood pressure and T2D are indicated for the management of CKD associated with T2D. Please consult the relevant SmPC before using any pharmacological treatment. Bayer does not encourage the use of any medicine out of its licensed indication.

Kerendia is the only licensed and NICE approved ns-MRA in UK for the treatment of patients with CKD (stages 3 & 4 with albuminuria) associated with type 2 diabetes⁸

Kerendia provides HCPs with an additional treatment option to help delay Chronic Kidney Disease progression in patients with Type 2 Diabetes

⁸

Kerendia is pharmacologically distinct from steroidal MRAs

¹¹

Adapted from Kolkhof¹¹

^**Statements are based on preclinical data and are not supported by human studies

Kerendia has not been compared to currently available MRAs in Phase 3 clinical trials; therefore, the clinical consequences of differences between the characteristics described is unknown.

In vitro, Kerendia is ≥500-fold more selective for the MR than for glucocorticoid, androgen, progesterone or oestrogen receptors (vs. ~3-fold for spironolactone)^12,13

Kerendia has a short half-life (2–3 hours in patients with CKD) and no active metabolites. Hyperkalaemia is a listed as a very common side effect of kerendia affecting ≥ 1/10 of patients. In the FIDELIO-DKD study, finerenone associated hyperkalaemia was most frequently managed by treatment interruption. For additional information please see safety & dosing section of the website.⁸